Search

Your search keyword '"Dimou M"' showing total 156 results

Search Constraints

Start Over You searched for: Author "Dimou M" Remove constraint Author: "Dimou M" Search Limiters Full Text Remove constraint Search Limiters: Full Text
156 results on '"Dimou M"'

Search Results

2. P1646: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN PATIENTS OLDER THAN 75 YEARS: REAL WORLD DATA FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY

3. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

4. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

5. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma

6. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies

7. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

8. Pembrolizumab-induced remission after failure of axicabtagene ciloleucel: Case report and literature review

9. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database

10. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas

11. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

12. Cumulative pollen concentration curves for pollen allergy diagnosis

13. Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood-brain barrier be a disease 'sanctuary' during venetoclax treatment?

14. Heterogeneity of pollen food allergy syndrome in seven Southern European countries: the @IT.2020 Multicenter Study

15. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

16. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes

18. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry

19. Frontline treatment with the combination obinutuzumab±chlorambucil for chronic lymphocytic leukemia outside clinical trials: results of a multinational, multicenter study by ERIC and the Israeli CLL study group

20. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study

21. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

22. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

23. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

24. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

27. Introduction

28. Low Bone Mineral Density and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

29. Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact

31. Chronic myelomonocytic leukemia treated with 5-azacytidine–results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system

32. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry

33. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

34. L'Odyssée revisitée, le retour de Circé, Réflexions sur le colloque ASRDLF, Athènes 2017

35. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome

36. Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

37. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

39. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial

40. PCN266 PATIENT, DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN GREECE: RESULTS FROM ANALYSIS OF A GREEK CLL-DATABASE

41. PS1192 INITIAL REPORT OF A NILOTINIB DISCONTINUATION PROJECT WITH 54 GREEK CML PATIENTS FOLLOWED IN ACCORDANCE TO THE APPROVED DISCONTINUATION INDICATION OF THE DRUG

42. S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

43. PF693 PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN THE ELRDELRY AND YOUNGER ADULTS: REAL-WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY

44. PB2079 INCIDENCE OF MBL AT MDS DIAGNOSIS AND CLINICAL IMPLICATIONS

45. Prognostic implication of the absolute lymphocyte to absolute monocyte count ratio in patients with classical hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens

46. Disulfides with Anti-inflammatory Activity from the Brown Alga Dictyopteris membranacea

47. The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia

49. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase 4, non--interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

50. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: A phase IV, non-interventional, observational study from the European research initiative on chronic lymphocytic leukemia

Catalog

Books, media, physical & digital resources